46 Biggest Movers From Yesterday

Gainers

• Theseus Pharmaceuticals, Inc. THRX gained 34.1% to settle at $12.58 on Wednesday.
• CMC Materials, Inc. CCMP climbed 33.9% to close at $195.50 on Wednesday after the company announced it will be acquired by Entegris for $6.5 billion in cash and stock.
• Biofrontera Inc. BFRI shares jumped 26.4% to settle at $6.95 on Wednesday after Benchmark initiated coverage on the stock with a Buy rating and announced a $11 price target.
• Regional Health Properties, Inc. RHE gained 23.8% to close at $6.70.
• Regional Health Props, last month, posted a Q3 loss of $1.25 per share.
• Gemini Therapeutics, Inc. GMTX rose 23.1% to settle at $2.99 after HC Wainwright & Co initiated coverage on the stock with a Buy rating and a $20 price target.
• CN Energy Group. Inc. CNEY jumped 22.4% to close at $3.01.
• Mesoblast Limited MESO climbed 19.2% to settle at $4.97. Mesoblast shares dropped around 28% on Tuesday after the company was notified by Novartis that it has chosen to terminate the agreement with Mesoblast prior to closing.
• Broadstone Acquisition Corp. BSN gained 19.1% to close at $10.68.
• Cabaletta Bio, Inc. CABA jumped 18.2% to settle at $3.97.
• Ensysce Biosciences, Inc. ENSC surged 17.4% to close at $4.11. Ensysce Biosciences said that the first patients have been enrolled in Phase 1 study of PF614-MPAR, its unique technology platform to provide opioid overdose protection.
• Trio-Tech International TRT gained 16.6% to close at $9.42.
• Aerovate Therapeutics, Inc. AVTE jumped 16.3% to close at $12.34 after the company announced the initiation of its IMPAHCT Phase 2b/Phase 3 trial of AV-101 In Pulmonary Arterial Hypertension.
• Optical Cable Corporation OCC gained 16.2% to settle at $6.40.
• Conn's, Inc. CONN rose 16.1% to close at $20.81. Conn's Board of Directors authorized a repurchase program of $150 million of its outstanding stock.
• Design Therapeutics, Inc. DSGN surged 16% to settle at $20.36.
• Bird Global, Inc. BRDS gained 15.7% to close at $8.97.
• VerifyMe, Inc. VRME jumped 13.7% to close at $3.65.
• East Stone Acquisition Corporation ESSC gained 12.9% to close at $15.24 after declining 26% on Tuesday.
• Vir Biotechnology, Inc. VIR gained 12.1% to close at $51.62 after the company announced new preclinical data demonstrating the impact of the significant antigenic shift of the new SARS-CoV-2 Omicron variant.
• SeaChange International, Inc. SEAC rose 11.9% to close at $1.69 after the company reported better-than-expected Q3 results.
• Nxt-ID, Inc. NXTD shares rose 11.7% to close at $2.78 after the company said it was awarded U.S. General Services Administration contract to distribute personal emergency response systems to Federal, State and Local government purchasers.
• Tandem Diabetes Care, Inc. TNDM climbed 10.5% to close at $144.34.
• Eli Lilly and Company LLY climbed 10.4% to close at $275.28 after the company issued FY21 EPS guidance above analyst estimates.
• Borr Drilling Limited BORR gained 9.2% to close at $1.67 after declining over 4% on Tuesday..
• Galera Therapeutics, Inc. GRTX gained 7.4% to close at $2.90 after BTIG upgraded the stock from Neutral to Buy and announced a $15 price target. Galera Therapeutics shares jumped around 96% on Tuesday after the company announced the primary endpoint met statistical significance in corrected topline efficacy data of Phase 3 ROMAN trial of avasopasem.

Check out these big penny stock gainers and losers

Losers

• Atai Life Sciences N.V. ATAI dropped 31.9% to close at $6.82 on Wednesday.
• China Xiangtai Food Co., Ltd. PLIN fell 28.2% to settle at $1.81. The company earlier announced the completion of its first purchase of spot Bitcoin miners worth $7 million.
• Aspen Group, Inc. ASPU shares declined 27.2% to close at $1.90 on Wednesday after the company reported worse-than-expected Q2 results and cut FY22 guidance.
• REV Group, Inc. REVG fell 25.5% to close at $11.87 after the company reported worse-than-expected Q4 EPS and sales results and issued FY22 sales guidance below estimates.
• Idera Pharmaceuticals, Inc. IDRA shares dipped 25.3% to close at $0.6501 on Wednesday after the company announced tilsotolimod updates. The company said no further enrollment in ILLUMINATE-206 trial is planned at this point.
• LianBio LIAN fell 21.3% to close at $7.68. LianBio reported a Q3 loss of $0.63 per share.
• The Oncology Institute, Inc. TOI fell 17.9% to close at $6.25.
• Alzamend Neuro, Inc. ALZN fell 15.9% to close at $2.59 after jumping 28% on Tuesday.
• LogicBio Therapeutics, Inc LOGC dropped 15.5% to close at $2.45. Barclays maintained LogicBio Therapeutics with an Overweight and lowered the price target from $24 to $8.
• Legend Biotech Corporation LEGN shares fell 15.3% to close at $41.14 after the company reported an offering of $300 million in ADSs.
• Huadi International Group Co., Ltd. HUDI fell 15% to close at $27.62.
• iSpecimen Inc. ISPC fell 13.3% to close at $10.87.
• MIND Technology, Inc. MIND shares fell 12.9% to close at $1.55. MIND Technology shares gained 30% on Tuesday after the company reported it entered into a Cooperative Research and Development Agreement with the United States Navy's Naval Surface Warfare Center, Panama City Division.
• Adagio Therapeutics, Inc. ADGI fell 12.5% to close at $6.35 after Stifel downgraded the stock from Buy to Hold and lowered the price target from $50 to $9. Adagio Therapeutics shares dipped 79% on Tuesday after the company said based on the in vitro findings related to Omicron, it plans to pause patient recruitment in its Phase 2/3 COVID-19 treatment trial at clinical sites in South Africa.
• Zai Lab Limited ZLAB fell 12.4% to close at $54.90.
• Cerence Inc. CRNC dropped 11.4% to close at $69.20. Cerence’s board promoted Dr. Stefan Ortmanns to Chief Executive Officer and Director.
• ABM Industries Incorporated ABM fell 11% to close at $40.88 as the company reported fourth-quarter revenue growth of 14.2% year-over-year to $1.69 billion, comprised of 7.4% organic growth and 6.8% from acquisition.
• BeiGene, Ltd. BGNE fell 10.7% to close at $248.56. BeiGene reported authorisation of BRUKINSA (zanubrutinib) from the UK’s MHRA for the treatment of adults with Waldenström’s Macroglobulinemia in Great Britain.
• Cooper-Standard Holdings Inc. CPS fell 7.1% to close at $19.71.
• Nisun International Enterprise Development Group Co., Ltd NISN fell 6.9% to close at $3.50.
• I-Mab IMAB fell 5% to close at $46.97. I-Mab received IND approval for Phase 1 clinical trial of bispecific antibody TJ-CD4B in solid tumors in China.